ceritinib
Showing 1 - 23 of 23
ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)
Terminated
- ALK-positive Non-small Cell Lung Cancer
- Ceritinib
- Stereotactic ablative body radiation
-
Dallas, TexasUT Southwestern Medical Center
Jan 31, 2023
ALK Positive Tumors Trial (ceritinib)
No longer available
- ALK Positive Tumors
- ceritinib
- (no location specified)
Nov 30, 2021
High-risk Neuroblastoma Trial in Charlotte (Naxitamab, Ceritinib)
Not yet recruiting
- High-risk Neuroblastoma
- Naxitamab
- Ceritinib
-
Charlotte, North CarolinaLevine Children's Hospital
Aug 4, 2022
Cancer Medicines in Metastatic Non-small Cell Lung Cancer in
Not yet recruiting
- Non-Small Cell Lung Cancer
- lorlatinib
- +17 more
-
Oslo, NorwayPfizer Norway
Apr 17, 2023
Neuroblastoma, Cancer Trial in Philadelphia (procedure, genetic, other, behavioral, drug)
Terminated
- Neuroblastoma
- Cancer
- Biopsy
- +12 more
-
Philadelphia, PennsylvaniaThe Children's Hospital of Philadelphia
Jan 31, 2023
ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase
Completed
- ALK-positive NSCLC
- crizotinib
- +4 more
-
Sollentuna, SwedenPfizer Innovations AB
Mar 14, 2022
NSCLC Trial in Worldwide (ceritinib)
Completed
- Non-Small Cell Lung Cancer
- ceritinib
-
Fayetteville, Arkansas
- +72 more
Feb 7, 2022
free Survival and Evaluate Participant Experience for Metastatic
Active, not recruiting
- Anaplastic Lymphoma Kinase-positive
- Carcinoma Non-small-cell Lung
- Brigatinib
- +4 more
-
Maynard, MassachusettsEmpiraMed, Inc.
Feb 28, 2022
NSCLC Trial in Worldwide (Ribociclib, Ceritinib)
Completed
- Non-small Cell Lung Cancer
- Ribociclib
- Ceritinib
-
Boston, Massachusetts
- +7 more
Dec 16, 2020
ALK-positive Advanced Tumors Trial in Worldwide (ceritinib, warfarin, midazolam)
Completed
- ALK-positive Advanced Tumors
- ceritinib
- +2 more
-
Detroit, Michigan
- +10 more
Dec 16, 2020
Tumors With Aberrations in ALK or ROS1 Trial in United States (Ceritinib)
Terminated
- Tumors With Aberrations in ALK or ROS1
- Ceritinib
-
Santa Rosa, California
- +20 more
Mar 12, 2021
Neuroblastoma Trial in United States (Ceritinib, dasatinib, sorafenib)
Recruiting
- Neuroblastoma
- Ceritinib
- +4 more
-
Birmingham, Alabama
- +23 more
Sep 26, 2022
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,
Terminated
- ALK Fusion Protein Expression
- +14 more
- Capmatinib
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 14, 2020
Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
Withdrawn
- Anaplastic Large Cell Lymphoma, ALK-Positive
- +2 more
- Brentuximab Vedotin
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 8, 2019
NSCLC Trial in Worldwide (Ceritinib, pemetrexed, docetaxel)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Ceritinib
- +2 more
-
Fayetteville, Arkansas
- +96 more
Dec 19, 2022
Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer Trial in Dallas (Ceritinib)
Withdrawn
- Metastatic Anaplastic Thyroid Cancer
- Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
- Ceritinib
-
Dallas, TexasUT Southwestern Medical Center
Jul 26, 2019
NSCLC Trial in Worldwide (Ceritinib, Pemetrexed, Cisplatin)
Active, not recruiting
- Non-Small Cell Lung Cancer
- Ceritinib
- +3 more
-
Woolloongabba, Queensland, Australia
- +131 more
Oct 24, 2022
ALK-positive NSCLC Trial in Worldwide (Ceritinib)
Completed
- ALK-positive Non-small Cell Lung Cancer
- Ceritinib
-
Los Angeles, California
- +56 more
Apr 8, 2020
Colorectal Adenocarcinoma, Cholangiocarcinoma, Pancreatic Adenocarcinoma Trial in United States (ceritinib)
Terminated
- Colorectal Adenocarcinoma
- +5 more
- ceritinib
-
Los Angeles, California
- +5 more
Mar 29, 2018
Hematologic Malignancies Trial in Durham (ceritinib)
Withdrawn
- Hematologic Malignancies
- ceritinib
-
Durham, North CarolinaDuke University Medical Center
Jan 30, 2017